Patents by Inventor Axel Ullrich

Axel Ullrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9458463
    Abstract: The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 4, 2016
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Mathias Falcenberg, Axel Ullrich
  • Patent number: 9206130
    Abstract: Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: December 8, 2015
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Pjotr Knyazev, Yixiang Zhang, Kéri György, László Örfi, István Szabadkai
  • Patent number: 9169241
    Abstract: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 27, 2015
    Assignee: Max-Planck-Gesellschaft Zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Robert Torka, Yixiang Zhang, György Kéri, László Örfi, István Szabadkai
  • Patent number: 9011851
    Abstract: The present invention relates to a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition for the diagnosis, prevention or treatment of hyperproliferative diseases, particularly tumor diseases is disclosed.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: April 21, 2015
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Edward Htun-Van Der Horst
  • Patent number: 8999982
    Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: April 7, 2015
    Assignees: Lead Discovery Center GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Axel Choidas, Uwe Koch, Jan Eickhoff, Alexander Wolf, Axel Ullrich
  • Publication number: 20150079108
    Abstract: The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 19, 2015
    Inventors: Mathias Falcenberg, Axel Ullrich
  • Publication number: 20140336191
    Abstract: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.
    Type: Application
    Filed: March 10, 2014
    Publication date: November 13, 2014
    Inventors: Axel Ullrich, Robert Torka, Yixiang Zhang, György Kéri, László Örfi, István Szabadkai
  • Patent number: 8685971
    Abstract: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.
    Type: Grant
    Filed: October 16, 2010
    Date of Patent: April 1, 2014
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Robert Torka, Yixiang Zhang, György Kéri, László Örfi, István Szabadkai
  • Publication number: 20140018365
    Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 26, 2011
    Publication date: January 16, 2014
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V., LEAD DISCOVERY CENTER GMBH
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Axel Choidas, Uwe Koch, Jan Eickhoff, Alexander Wolf, Axel Ullrich
  • Publication number: 20130336986
    Abstract: The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, and GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
    Type: Application
    Filed: September 5, 2011
    Publication date: December 19, 2013
    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Mathias Falcenberg, Axel Ullrich
  • Patent number: 8591903
    Abstract: The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an organism comprising inhibiting the activity of the metalloprotease TACE/ADAM17 and/or the activity of the receptor tyrosine kinase ligand amphiregulin.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: November 26, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Andreas Gschwind, Stefan Hart
  • Patent number: 8557768
    Abstract: The ?-subunit of human nerve growth factor (?NGF) is prepared in essentially pure form in commercially useful quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human ?NGF and host cells transformed with the vectors are also provided. The ?NGF which the invention provides is useful, for example, in treating nerve damage.
    Type: Grant
    Filed: April 4, 1995
    Date of Patent: October 15, 2013
    Assignee: Genentech, Inc.
    Inventors: Alane M. Gray, Axel Ullrich
  • Publication number: 20130084300
    Abstract: The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.
    Type: Application
    Filed: August 31, 2012
    Publication date: April 4, 2013
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Axel ULLRICH, Pjotr Knyazev, Tatjana Knyazeva, Yuri Cheburkin
  • Publication number: 20120277231
    Abstract: The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.
    Type: Application
    Filed: October 16, 2010
    Publication date: November 1, 2012
    Inventors: Axel Ullrich, Robert Torku, Yixiang Zhang, György Kéri, László Örfi, István Szabadkai
  • Patent number: 8277802
    Abstract: The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. Most particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: October 2, 2012
    Assignee: Max-Planck-Gesellschaft zur Foederung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Pjotr Knyazev, Tatjana Knyazeva, Yuri Cheburkin, Peter Vajkoczy
  • Patent number: 8043806
    Abstract: The invention provides method of diagnosing a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder or a genetic predisposition therefor in a mammal. The method comprises determining the presence of a nucleic acid encoding a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample from a mammal. The presence of a nucleic acid encoding a mutated FGFR-4 protein is indicative of an RTK-hyperfunction-induced disorder or a genetic predisposition therefor.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: October 25, 2011
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
  • Publication number: 20110179505
    Abstract: The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4.
    Type: Application
    Filed: September 29, 2009
    Publication date: July 21, 2011
    Applicant: MAX-PLANCK-GESELLSCHAGFT zur FOERDERUNG der WISSENSCHAFTEN e.V.
    Inventors: Axel Ullrich, Thomas Mayer, Sylvia Streit, Nina Seitzer
  • Patent number: 7964399
    Abstract: The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention s based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: June 21, 2011
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Yissum Research, Development Company of the Hebrew University of Jerusalem
    Inventors: Axel Ullrich, Werner Risau, Birgit Millauer, Aviv Gazit, Alex Levitzki
  • Publication number: 20110092503
    Abstract: Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.
    Type: Application
    Filed: April 16, 2009
    Publication date: April 21, 2011
    Inventors: Axel Ullrich, Pjotr Knyazev, Yixiang Zhang, Kéri György, László Örfi, István Szabadkai
  • Patent number: D960385
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 9, 2022
    Assignee: Abbott Rapid Diagnostics International Unlimited Company
    Inventors: Axel Schubert, Thomas Ullrich, Sören Geist, Martin Stohr, Christopher Deppisch, Michael Winterot, Ilka Schlesiger